Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

1,868.00p
   
  • Change Today:
    -30.00p
  • 52 Week High: 2,590.00p
  • 52 Week Low: 1,637.00p
  • Currency: UK Pounds
  • Shares Issued: 66.03m
  • Volume: 57,446
  • Market Cap: £1,233.49m
  • RiskGrade: 128

Genus' long-running legal battle with Sexing Technologies rumbles on

By Oliver Haill

Date: Friday 09 Jun 2017

LONDON (ShareCast) - (ShareCast News) - The long-running legal battle between animal genetics specialist Genus and US rival Sexing Technologies' owner Inguran rumbles on, with the UK company accused of infringing patents and breaching trade secrets.
Genus said it intends to vigorously defend itself against new litigation in the US, as rival ST filed patent infringement proceedings against Genus and its subsidiaries ABS Global and Premium Genetics in a Wisconsin district court, alleging that ABS infringed seven ST patents and asserted trade secret and breach of contract claims.

In April in the same western district of Wisconsin, Genus won its litigation case against ST and Inguran, with a court removed various contractual restrictions that had been blocking the way for Genus subsidiary ABS Global to commercially launch the Genus Sexed Semen (GSS) programme.

GSS, is a proprietary product Genus has designed to compete with ST's monopoly in the processing of sexed bovine semen.

The UK company noted that in April's results, where it launched litigation against ST, the court awarded ABS a permanent injunction against ST based on the finding that ST had wilfully maintained an illegal monopoly in the market for sexed bovine semen processing in the US since July 2012, and had found ABS had infringed two ST patents and awarded damages and post judgment royalties.

"ABS has filed a notice of appeal on one of these patents and an Inter-Partes Review oral hearing at the US Patent Office is scheduled shortly on the other. The US Patent Office had earlier found two other ST patents challenged by ABS to be unpatentable," it confirmed.

"GSS is a novel and proprietary technology for sexing bovine semen that focuses on fertility outcomes and does not subject the sperm cells to the high pressures and sheer forces of the technology currently in use in the industry.

"The new litigation will not delay the commercial launch of GSS which will launch as scheduled in 2017 in the US and other key markets," the FTSE 250 company said.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genus Market Data

Currency UK Pounds
Share Price 1,868.00p
Change Today -30.00p
% Change -1.58 %
52 Week High 2,590.00p
52 Week Low 1,637.00p
Volume 57,446
Shares Issued 66.03m
Market Cap £1,233.49m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
96.04% below the market average96.04% below the market average96.04% below the market average96.04% below the market average96.04% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
53.64% below the market average53.64% below the market average53.64% below the market average53.64% below the market average53.64% below the market average
18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average
Income
86.4% below the market average86.4% below the market average86.4% below the market average86.4% below the market average86.4% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
67.9% below the market average67.9% below the market average67.9% below the market average67.9% below the market average67.9% below the market average
64.71% below the sector average64.71% below the sector average64.71% below the sector average64.71% below the sector average64.71% below the sector average

What The Brokers Say

Strong Buy 5
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 7
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 29-Feb-24 09-Nov-23
Paid 28-Mar-24 08-Dec-23
Amount 10.30p 21.70p

Trades for 13-May-2024

Time Volume / Share Price
16:11 2 @ 1,866.00p
16:35 34,896 @ 1,868.00p
16:35 2 @ 1,868.00p
16:35 181 @ 1,868.00p
16:35 90 @ 1,868.00p

Genus Key Personnel

CFO Alison Henriksen
CEO Jorgen Kokke

Top of Page